Vascular endothelial growth factor antisense oligodeoxynucleotides with lipidol in arterial embolization of liver cancer in rats

Han Ping Wu, Gan Sheng Feng, Hui Min Liang, Chuan Sheng Zhen, Xin Li

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aim: Transcatheter arterial embolization (TAE) of the hepatic artery has been accepted as an effective treatment for unresectable hepatocellular carcinoma (HCC). However, embolized vessel recanalization and collateral circulation formation are the main factors of HCC growth and recurrence and metastasis after TAE. Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis. This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Methods: VEGF antisense ODNs and sense ODNs were added to the media of non-serum cultured Walker-256 cells. Forty-eight hours later, VEGF concentrations of supernatants were detected by ELISA. Endothelial cell line ECV-304 cells were cultured in the supernatants. Seventy-two hours later, growth of ECV-304 cells was analyzed by MTT method. Thirty Walker-256 cell implanted rat liver tumor models were divided into 3 groups. 0.2 mL lipiodol (LP group, n=10), 3OD antisense ODNs mixed with 0.2 mL lipiodol (LP+ODNs group, n=10) and 0.2 mL normal saline (control group, n=10) were infused into the hepatic artery. Volumes of tumors were measured by MRI before and 7 d after the treatment. VEGF mRNA in cancerous and peri-cancerous tissues was detected by RT-PCR. Microvessel density (MVD) and VEGF expression were observed by immunohistochemistry. Results: Antisense ODNs inhibited Walker-256 cells' VEGF expression. The tumor growth rate was significantly lower in LP+ODNs group than that in LP and control groups (140.1±33.8%, 177.9±64.9% and 403.9±69.4% respectively, F=60.019, P0.05). The MVD in LP+ODNs group (53.1±18.4 was significantly less than that in control group (73.2±20.4) and LP group (80.3±18.5) (F=5.44, P

Original languageEnglish (US)
Pages (from-to)813-818
Number of pages6
JournalWorld Journal of Gastroenterology
Volume10
Issue number6
StatePublished - Mar 15 2004
Externally publishedYes

Fingerprint

Oligodeoxyribonucleotides
Liver Neoplasms
Vascular Endothelial Growth Factor A
Walkers
Ethiodized Oil
Hepatic Artery
Microvessels
Control Groups
Hepatocellular Carcinoma
Neoplasms
Growth
Intra Arterial Infusions
Collateral Circulation
Tumor Burden
Cultured Cells
Endothelial Cells
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Vascular endothelial growth factor antisense oligodeoxynucleotides with lipidol in arterial embolization of liver cancer in rats. / Wu, Han Ping; Feng, Gan Sheng; Liang, Hui Min; Zhen, Chuan Sheng; Li, Xin.

In: World Journal of Gastroenterology, Vol. 10, No. 6, 15.03.2004, p. 813-818.

Research output: Contribution to journalArticle

Wu, Han Ping ; Feng, Gan Sheng ; Liang, Hui Min ; Zhen, Chuan Sheng ; Li, Xin. / Vascular endothelial growth factor antisense oligodeoxynucleotides with lipidol in arterial embolization of liver cancer in rats. In: World Journal of Gastroenterology. 2004 ; Vol. 10, No. 6. pp. 813-818.
@article{ca617254663c4be1894c548180f9d9fb,
title = "Vascular endothelial growth factor antisense oligodeoxynucleotides with lipidol in arterial embolization of liver cancer in rats",
abstract = "Aim: Transcatheter arterial embolization (TAE) of the hepatic artery has been accepted as an effective treatment for unresectable hepatocellular carcinoma (HCC). However, embolized vessel recanalization and collateral circulation formation are the main factors of HCC growth and recurrence and metastasis after TAE. Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis. This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Methods: VEGF antisense ODNs and sense ODNs were added to the media of non-serum cultured Walker-256 cells. Forty-eight hours later, VEGF concentrations of supernatants were detected by ELISA. Endothelial cell line ECV-304 cells were cultured in the supernatants. Seventy-two hours later, growth of ECV-304 cells was analyzed by MTT method. Thirty Walker-256 cell implanted rat liver tumor models were divided into 3 groups. 0.2 mL lipiodol (LP group, n=10), 3OD antisense ODNs mixed with 0.2 mL lipiodol (LP+ODNs group, n=10) and 0.2 mL normal saline (control group, n=10) were infused into the hepatic artery. Volumes of tumors were measured by MRI before and 7 d after the treatment. VEGF mRNA in cancerous and peri-cancerous tissues was detected by RT-PCR. Microvessel density (MVD) and VEGF expression were observed by immunohistochemistry. Results: Antisense ODNs inhibited Walker-256 cells' VEGF expression. The tumor growth rate was significantly lower in LP+ODNs group than that in LP and control groups (140.1±33.8{\%}, 177.9±64.9{\%} and 403.9±69.4{\%} respectively, F=60.019, P0.05). The MVD in LP+ODNs group (53.1±18.4 was significantly less than that in control group (73.2±20.4) and LP group (80.3±18.5) (F=5.44, P",
author = "Wu, {Han Ping} and Feng, {Gan Sheng} and Liang, {Hui Min} and Zhen, {Chuan Sheng} and Xin Li",
year = "2004",
month = "3",
day = "15",
language = "English (US)",
volume = "10",
pages = "813--818",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "6",

}

TY - JOUR

T1 - Vascular endothelial growth factor antisense oligodeoxynucleotides with lipidol in arterial embolization of liver cancer in rats

AU - Wu, Han Ping

AU - Feng, Gan Sheng

AU - Liang, Hui Min

AU - Zhen, Chuan Sheng

AU - Li, Xin

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Aim: Transcatheter arterial embolization (TAE) of the hepatic artery has been accepted as an effective treatment for unresectable hepatocellular carcinoma (HCC). However, embolized vessel recanalization and collateral circulation formation are the main factors of HCC growth and recurrence and metastasis after TAE. Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis. This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Methods: VEGF antisense ODNs and sense ODNs were added to the media of non-serum cultured Walker-256 cells. Forty-eight hours later, VEGF concentrations of supernatants were detected by ELISA. Endothelial cell line ECV-304 cells were cultured in the supernatants. Seventy-two hours later, growth of ECV-304 cells was analyzed by MTT method. Thirty Walker-256 cell implanted rat liver tumor models were divided into 3 groups. 0.2 mL lipiodol (LP group, n=10), 3OD antisense ODNs mixed with 0.2 mL lipiodol (LP+ODNs group, n=10) and 0.2 mL normal saline (control group, n=10) were infused into the hepatic artery. Volumes of tumors were measured by MRI before and 7 d after the treatment. VEGF mRNA in cancerous and peri-cancerous tissues was detected by RT-PCR. Microvessel density (MVD) and VEGF expression were observed by immunohistochemistry. Results: Antisense ODNs inhibited Walker-256 cells' VEGF expression. The tumor growth rate was significantly lower in LP+ODNs group than that in LP and control groups (140.1±33.8%, 177.9±64.9% and 403.9±69.4% respectively, F=60.019, P0.05). The MVD in LP+ODNs group (53.1±18.4 was significantly less than that in control group (73.2±20.4) and LP group (80.3±18.5) (F=5.44, P

AB - Aim: Transcatheter arterial embolization (TAE) of the hepatic artery has been accepted as an effective treatment for unresectable hepatocellular carcinoma (HCC). However, embolized vessel recanalization and collateral circulation formation are the main factors of HCC growth and recurrence and metastasis after TAE. Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis. This study was to explore the inhibitory effect of VEGF antisense oligodeoxynucleotides (ODNs) on VEGF expression in cultured Walker-256 cells and to observe the anti-tumor effect of intra-arterial infusion of antisense ODNs mixed with lipiodol on rat liver cancer. Methods: VEGF antisense ODNs and sense ODNs were added to the media of non-serum cultured Walker-256 cells. Forty-eight hours later, VEGF concentrations of supernatants were detected by ELISA. Endothelial cell line ECV-304 cells were cultured in the supernatants. Seventy-two hours later, growth of ECV-304 cells was analyzed by MTT method. Thirty Walker-256 cell implanted rat liver tumor models were divided into 3 groups. 0.2 mL lipiodol (LP group, n=10), 3OD antisense ODNs mixed with 0.2 mL lipiodol (LP+ODNs group, n=10) and 0.2 mL normal saline (control group, n=10) were infused into the hepatic artery. Volumes of tumors were measured by MRI before and 7 d after the treatment. VEGF mRNA in cancerous and peri-cancerous tissues was detected by RT-PCR. Microvessel density (MVD) and VEGF expression were observed by immunohistochemistry. Results: Antisense ODNs inhibited Walker-256 cells' VEGF expression. The tumor growth rate was significantly lower in LP+ODNs group than that in LP and control groups (140.1±33.8%, 177.9±64.9% and 403.9±69.4% respectively, F=60.019, P0.05). The MVD in LP+ODNs group (53.1±18.4 was significantly less than that in control group (73.2±20.4) and LP group (80.3±18.5) (F=5.44, P

UR - http://www.scopus.com/inward/record.url?scp=1842430783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842430783&partnerID=8YFLogxK

M3 - Article

C2 - 15040023

AN - SCOPUS:1842430783

VL - 10

SP - 813

EP - 818

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 6

ER -